Table 4.

Evaluation of the Presence of LGL in the Different T-Cell Subsets

Patients and ControlsLymphocytes (per μL)LGL4-150
PBLCD4+CD4CD4+CD57CD4CD57LGL4-151
%μL%μL%μL%μL%μLCD4+CD57+CD4CD57+
%μL%μL
ROPI 2,703 24 649 104 23 138 26 64 104 41 112 
GEGU 1,861 130 17 10 60 10 13 53 
LOME 1,251 37 463 11 64 30 146 11 56 59 40 135 
MAGHI 1,860 30 558 54 45 167 16 35 29 54 85 132 
Controls 2,009 ± 399 14.3 ± 2.2 247.6 ± 71.3 1.2 ± 1.2 12 ± 10 29 ± 11 179 ± 66  —   —   —   —   —   —   —   —  
Patients and ControlsLymphocytes (per μL)LGL4-150
PBLCD4+CD4CD4+CD57CD4CD57LGL4-151
%μL%μL%μL%μL%μLCD4+CD57+CD4CD57+
%μL%μL
ROPI 2,703 24 649 104 23 138 26 64 104 41 112 
GEGU 1,861 130 17 10 60 10 13 53 
LOME 1,251 37 463 11 64 30 146 11 56 59 40 135 
MAGHI 1,860 30 558 54 45 167 16 35 29 54 85 132 
Controls 2,009 ± 399 14.3 ± 2.2 247.6 ± 71.3 1.2 ± 1.2 12 ± 10 29 ± 11 179 ± 66  —   —   —   —   —   —   —   —  
F4-150

The percentage of LGL was evaluated morphologically, while the number of LGL/μL was calculated on the basis of the number of cells with the indicated phenotype.

F4-151

The number of LGL/μL in the two T-cell subpopulations was deduced by respectively subtracting from the number of LGL found in the CD4+ and CD4 subsets the number of LGL found in the CD4+CD57 and CD4CD57 cell populations. The percentage of LGL was calculated on the basis of the number of total CD4+CD57+ and CD8+CD57+ circulating lymphocytes.

Close Modal

or Create an Account

Close Modal
Close Modal